Key result
Acute and short-term mexiletine therapy suppressed recurrent ventricular tachycardia in 75% (6 of 8) of patients, with 5 of 6 remaining asymptomatic during a mean 15-month follow-up.
Why the study?
Does mexiletine therapy suppress arrhythmia in patients with recurrent ventricular tachycardia?
Observational (n=8)
Does mexiletine therapy suppress arrhythmia in patients with recurrent ventricular tachycardia?
Acute and short-term response to mexiletine can predict long-term arrhythmia suppression in patients with recurrent ventricular tachycardia.
May warrant short-term mexiletine trial in recurrent VT; leaves open confirmation in prospective studies.
Acute intravenous and short-term oral mexiletine therapy was effective in suppressing the arrhythmia in six of eight patients with recurrent ventricular tachycardia. Five of the six patients who were placed on maintenance therapy remained asymptomatic during a mean follow-up of 15 months. The study shows that the acute and short-term suppression of ventricular tachycardia by mexiletine can be a useful predictor of its long-term efficacy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (1983) conducted an observational in Recurrent ventricular tachycardia (n=8). Mexiletine was evaluated on Suppression of the arrhythmia. Acute and short-term mexiletine therapy suppressed recurrent ventricular tachycardia in 75% (6 of 8) of patients, with 5 of 6 remaining asymptomatic during a mean 15-month follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: